CLZ-8

SKU: orb1707002

Description

CLZ-8 (Mcl1-IN-8) is an orally bioavailable, radioprotective small molecule that inhibits the Mcl-1/PUMA interaction. It mitigates radiation-induced apoptosis and cellular damage in HUVECs in vitro by suppressing PUMA overexpression, showing potential for research in radiation biology and apoptosis signaling pathways.

Research Area

Cell Biology

Key Properties

• CAS Number: 678158-55-9
• MW: 393.5
• Purity: 99.85% (May vary between batches)
• Formula: C₂₂H₂₃N₃O₂S
• SMILES: OCCN1CCN(CC1)C1=NC(=O)\C(S1)=C\c1ccc(cc1)-c1ccccc1
• Target: Bcl-2 Family,Apoptosis
• Solubility: DMSO:40 mg/mL (101.65 mM);10% DMSO+90% Corn Oil:1 mg/mL (2.54 mM)

Bioactivity

• Target IC50:
  MCL1:0.3 μM (Ki)
• In Vivo:
  In 6-8 week-old male BALB/c mice, CLZ-8 (100, 200, and 400 mg/kg; intragastric administration, once, 30 minutes prior to irradiation) increases the survival rate of irradiated mice.
• In Vitro:
  In DLD-1 cells or HUVEC cells, CLZ-8 (0-160 μM; 48 hours for DLD-1 or 24 hours for HUVECs) significantly inhibits PUMA-dependent apoptosis with an IC50 of 38.93 ± 0.91 μM and attenuates radiation-induced apoptosis.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CLZ 8, CLZ8, Mcl-1, Mcl1 IN 8, Mcl1IN8, Mcl-1-IN-8, Mcl1-IN-8

Compound Identifiers

PubChem CID

988971